Voyageur Pharmaceuticals Ltd.
VYYRF
$0.13
$0.0218.90%
OTC PK
| 08/31/2025 | 05/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 189.79% | -43.08% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 193.44% | -43.06% | |||
| Operating Income | -190.44% | 43.06% | |||
| Income Before Tax | -145.72% | 32.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -145.72% | 32.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -145.72% | 32.24% | |||
| EBIT | -190.44% | 43.06% | |||
| EBITDA | -190.58% | 43.08% | |||
| EPS Basic | -137.50% | 35.14% | |||
| Normalized Basic EPS | -140.00% | 34.78% | |||
| EPS Diluted | -137.50% | 35.14% | |||
| Normalized Diluted EPS | -140.00% | 34.78% | |||
| Average Basic Shares Outstanding | 3.90% | 3.63% | |||
| Average Diluted Shares Outstanding | 3.90% | 3.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||